LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Cholesterol Diagnosis Related to Breast Cancer Risk

By LabMedica International staff writers
Posted on 22 Sep 2017
Print article
Image: Histopathology of breast cancer: intraductal carcinoma, comedo type, with distended duct with intact basement membrane and central tumor necrosis (Photo courtesy of Peter Abdelmessieh, DO, MSc).
Image: Histopathology of breast cancer: intraductal carcinoma, comedo type, with distended duct with intact basement membrane and central tumor necrosis (Photo courtesy of Peter Abdelmessieh, DO, MSc).
Breast cancer is a malignancy that begins when cells grow abnormally in breast tissue. Although men can also develop breast cancer, it is much more common in women. Among women around the globe, breast cancer is the most common cancer and the fifth most common cause of cancer death. In 2012, nearly 1.7 million new cases, a quarter of all new cancer cases in women, were diagnosed worldwide.

All animal cells need cholesterol to function normally and it is an essential component of cell walls. Cholesterol is also important for making vitamin D, compounds that aid digestion, and hormones. The blood transports cholesterol around the body inside lipoproteins, which are droplets of fat covered with protein. However, having too much cholesterol in the blood is a well-established risk factor for cardiovascular conditions.

Scientists at Aston University (Birmingham, UK) collected information from over one million patients attending several hospitals in the North West of England between 2000 and 2013. They searched records from female participants aged 40 and over who were and were not diagnosed with high cholesterol at baseline (the start of the study period) and did not have breast cancer at that point. For their analysis, the team included 16,043 women who were diagnosed with high cholesterol and an age-matched group of the same number of women without high cholesterol for comparison. The average age of the women was 66 years.

The investigators found a lower proportion of the high-cholesterol group developed breast cancer, compared with the group that did not receive such a diagnosis at baseline (0.5% compared with 0.8%). Further analysis revealed significantly lower odds of breast cancer in the high-cholesterol patients (odds ratio of 0.67), compared with the patients who had not received such a diagnosis. The group that had been diagnosed with high cholesterol at baseline also had lower rates of death compared with the group that had not (13.8% compared with 23.7%). After taking into account age, ethnicity, and other factors known to influence premature death, the team found that the high-cholesterol group had significantly lower odds of death (odds ratio 0.60).

The team concluded that their large, longitudinal, retrospective study shows that diagnosis of high cholesterol has a highly protective effect on the subsequent development of breast cancer. Rahul Potluri, MD, a clinical scientist and the senior author of the study said, “If a diagnosis of high cholesterol leads to lower breast cancer rates this must either relate to something inherent in the condition or affected patients, or more likely, to treatment with widely used cholesterol lowering interventions such as statins.” The study was presented at the European Society of Cardiology ESC Congress, held August 26-30, 2017, in Barcelona, Spain.

Related Links:
Aston University

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Deliver Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.